BPC January 07 update

JP Morgan Conference Schedule; Odonate ODT -17% NASDAQ delisting

Price and Volume Movers

Odonate Therapeutics, Inc. (NASDAQ: ODT) received written notice stating that Nasdaq believes that Odonate is a "public shell" pursuant to Listing Rule 5101. Its shares will be delisted January 18, 2022 and Odonate will not appeal this determination. Shares closed down 17% at $1.09.

Glaukos Corporation (NYSE: GKOS) announced that it has received 510(k) clearance from the FDA for the iPRIME Viscodelivery System for the delivery of viscoelastic fluid during ophthalmic surgery. Shares closed up 5% at $47.55.

Vigil Neuroscience (NASDAQ: VIGL) shares fell 12% during its IPO debut. Vigil priced 7 million shares at $14 per share but it tumbled to $12.05 after opening. Shares closed down 10% at $12.65.

Piper Sandler raises Amphastar (NASDAQ: AMPH) to Overweight from neutral, citing improving visibility into the company's pipeline of complex generics and insulin biosimilars. Shares closed up 8% at $25.05.

Exscientia Plc (NASDAQ: EXAI) and Sanofi (NASDAQ: SNY) announced a research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology. Exscientia will receive an upfront cash payment of $100 million and $5.2 billion in milestones plus royalties. Shares closed up 10% at $20.06.

Advancers

CompanyPriceChange
ARDS
Aridis Pharmaceuticals Inc.
$1.60+0.27  +20.30%
CINC
CinCor Pharma Inc.
$18.20+2.13  +13.25%
RVLP
RVL Pharmaceuticals plc
$1.20+0.11  +10.09%
ITCI
Intra-Cellular Therapies Inc.
$42.66+3.79  +9.75%
GMDA
Gamida Cell Ltd.
$3.24+0.28  +9.46%
HILS
Hillstream BioPharma Inc.
$3.36+0.23  +7.35%
KPTI
Karyopharm Therapeutics Inc.
$8.28+0.55  +7.12%
CNTX
Context Therapeutics Inc.
$2.10+0.13  +6.60%
LABD
Direxion Daily S&P Biotech Bear 3X Shares
$45.71+2.71  +6.30%
BDSI
BioDelivery Sciences International Inc.
$3.36+0.18  +5.66%

Decliners

CompanyPriceChange
IMMX
Immix Biopharma Inc.
$4.51-0.91  -16.79%
ACXP
Acurx Pharmaceuticals Inc.
$3.64-0.7  -16.13%
CGTX
Cognition Therapeutics Inc.
$3.50-0.64  -15.46%
HOOK
HOOKIPA Pharma Inc.
$1.50-0.26  -14.77%
CVAC
CureVac N.V.
$18.73-3.12  -14.28%
BFRI
Biofrontera Inc.
$3.47-0.53  -13.25%
BSGM
BioSig Technologies Inc.
$1.80-0.27  -13.04%
HCWB
HCW Biologics Inc.
$2.02-0.3  -12.93%
VRPX
Virpax Pharmaceuticals Inc.
$2.30-0.34  -12.88%
APM
Aptorum Group Limited
$1.48-0.21  -12.43%

Pipeline Database Updates

Drug Price Stage Catalyst Market Cap

ABBV – AbbVie Inc.
RINVOQ (upadacitinib) - (SELECT-AXIS 2)
Non-radiographic axial spondyloarthritis

$131.98
-1.05  -1%
sNDA Filing sNDA submitted to FDA January 7, 2021.
$233.3 billion

AVIR – Atea Pharmaceuticals Inc.
AT-752
Dengue

$6.44
-0.48  -7%
Phase 1 Phase 1 trial initiated 3Q 2021, Phase 2 trial planned to be initiated 1H 2022. Phase 2 topline data expected late 2022.
$535.2 million

AVIR – Atea Pharmaceuticals Inc.
Bemnifosbuvir (AT-527) - (Outpatient study)
COVID-19

$6.44
-0.48  -7%
Phase 2 Phase 2 data released June 30, 2021 - generally safe and well tolerated. In this hospitalized study, there were no drug-related serious adverse events. Changed hospitalized study setting to an outpatient study, noted January 7, 2022. Enrollment to be expanded with Phase 2 data due in late 2022.
$535.2 million

BCRX – BioCryst Pharmaceuticals Inc.
BCX9930 - (REDEEM-1)
Paroxysmal nocturnal hemoglobinuria (PNH)

$13.78
-0.20  -1%
Phase 3 Phase 3 trial enrollment initiated, noted January 10, 2022. Phase 3 data expected in 2024.
$2.5 billion

GMDA – Gamida Cell Ltd.
NiCord (omidubicel)
Hematologic Malignancies

$3.24
+0.28  +9%
Phase 3 Phase 3 data demonstrated rapid and sustained T cell and B cell recovery following transplantation with omidubicel in a subset of patients, noted December 11, 2021. Phase 3 data to be presented at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings (TCT) February 2-6, 2022. BLA filing due 1H 2022.
$192.1 million

RVNC – Revance Therapeutics Inc.
DaxibotulinumtoxinA
Moderate to severe glabellar (frown) lines

$13.43
-0.60  -4%
CRL CRL announced October 15, 2021. Resubmission of BLA planned.
$964.2 million